GSK Leads Target-Validation Collaboration With EBI And Wellcome Trust
This article was originally published in The Pink Sheet Daily
Executive Summary
Following its February participation in the NIH-led Accelerating Medicines Partnership, GSK now is joining with the European Bioinformatics Institute and Wellcome Trust Sanger Institute on a broad-based target-validation effort headquartered in the U.K. The collaboration’s work will be non-competitive and available to all.
You may also be interested in...
NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research
With $230 million from industry and NIH, the Accelerating Medicines Partnership will seek to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.